item management s discussion and analysis of financial condition and results of operations the following discussion should be read in conjunction with the financial statements and the notes thereto which are set forth elsewhere herein 
overview on february   the company acquired all of the assets and certain liabilities of escalon ophthalmics  inc prior to the acquisition  the company was in the development stage and devoting substantially all of its resources to the research and development of laser systems designed for the treatment of ophthalmic disorders 
upon completion of the acquisition  the company changed its market focus and is now engaged in developing  marketing and distributing ophthalmic medical devices  pharmaceuticals and niche medical products 
the company is continuing development of its ophthalmic drug delivery system to complement its other businesses 
sales of products acquired from eoi are made primarily to hospitals and physicians throughout the united states 
escalon purchased the vascular access business unit of radiance medical systems  inc in january this was significant as the company s first step in diversification 
the vascular access product line is the first niche product acquired outside the ophthalmic medical field 
vascular products are marketed to the pediatric and critical care providers through a series of independent distributors 
escalon s market strategy is to locate and acquire profitable niche medical products that it owns and controls the rights to 
to finance this program  the company in march sold its license and distribution rights to betadine r sterile ophthalmic prep solution to alcon 
subsequent to year end  it also sold the license and distribution rights to adatosil r silicone oil 
to further develop and commercialize its proprietary laser technology  in october  the company licensed its intellectual laser properties to a newly formed company  intralase  in return for an equity interest in intralase and future royalties on product sales 
intralase has the responsibility of funding and developing the laser technology through to commercialization 
the company expects that results of operations may fluctuate from quarter to quarter for a number of reasons  including i anticipated order and shipment patterns of the company s products  ii lead times to produce the company s products  and iii general competitive and economic conditions of the health care market 
results of operations years ended june  and product revenues increased to  in fiscal year from  in fiscal year this increase of  or  is due to the increase in unit sales of adatosil r silicone oil  vascular access products  contract manufactured equipment and ispan tm intraocular gases 
these increases were negatively impacted by a decrease in unit sales of the company s equipment  related disposable product lines and betadine r sterile ophthalmic prep solution this product line was sold in march 
contract manufacturing revenues vary from quarter to quarter depending on when orders are received and the lead times to produce such products 
cost of goods sold totaled  or of revenues  for fiscal year as compared to  or of revenues  for the year ended june  the slight decrease in cost of goods sold as a percentage of revenues is due primarily to a change in the product sales mix during the respective periods  with the addition of vascular access products and the disposal of the betadine product line 
research and development expenses increased from  in fiscal year to  in fiscal year  an increase of  or 
this represents increased spending for ocufit sr r  which entered the clinical trial stage  and preliminary spending for providone iodine solution  which will enter that stage of development by the second quarter of fiscal  these categories contributed  over fiscal spending 
the addition of vascular access manufacturing to the wisconsin facility caused the company to incur  in additional costs  in preparation for the relocation 
the abandonment of two medical patents and additional iso expenses contributed  and  respectively 
staffing levels for wisconsin also increased to help prepare for future growth and maintain the required documentation for the iso ce program 
marketing and general and administrative expenses increased  or  to  for the year ended june  as compared to  in fiscal year administrative  sales and marketing costs for five and a half months to promote vascular access products accounted for  intralase s fiscal contribution to intellectual property costs incurred by escalon also reduced expenses by  marketing and administrative expenses related to the ophthalmic business declined  from those reported in fiscal in march  the company reported the sale of its inventory  license and distribution rights for betadine r sterile ophthalmic prep solution 
this sale resulted in a  gain  after adjusting for the cost of inventory sold  and the write off of the remaining goodwill and license and distribution rights associated with that product line 
interest income increased to  in fiscal year from  in fiscal year this increase is due to greater levels of cash and cash equivalents available for investment  the result of the product line sale  aggressive collection efforts and corporate borrowing 
interest expense increased  to  in fiscal in february  the company obtained a million credit facility from pnc bank  na this marks the first time the company gained access to traditional mainstream financing sources 
as a result of this financing  escalon obtained a million five year term loan and access to a million line of credit 
in prior years  interest expense was virtually non existent since the company had no borrowing capability 
years ended june  and product revenues increased to  in fiscal year from  in fiscal year this increase of  or  is due to the increase in unit sales of adatosil r silicone oil  betadine r sterile ophthalmic prep solution and ispan tm intraocular gases 
these increases were partially offset by a decrease in unit sales of the company s capital equipment  related disposable product lines and contract manufacturing product lines 
contract manufacturing revenues vary from quarter to quarter depending on when orders are received and the lead times to produce such products 
cost of goods sold totaled  or of revenues  for fiscal year as compared to  or of revenues  for the year ended june  the decrease in cost of goods sold as a percentage of revenues is due primarily to i the strengthening of the us dollar against the german mark which has lowered the cost associated with the purchases of adatosil r silicone oil  the company s primary product  and ii a change in the product sales mix during the respective periods 
research and development expenses decreased from  in fiscal year to  in fiscal year  a decrease of  or 
this decrease relates to the elimination of expenditures associated with the company s laser development program  as a result of the company s change in market focus  and a decrease in expenditures associated with the company s drug delivery technology 
marketing and general and administrative expenses decreased  or  to  for the year ended june  as compared to  in fiscal year this decrease is due principally to i the reduction in the amortization expense of goodwill and license and distribution rights resulting from the write down of such assets during the fourth quarter of fiscal  and ii the decrease in commission expense as a result of a change in the company s commission structure 
these decreases were offset partially by costs associated with the closing of the company s new jersey office and relocation of the company s wisconsin production facility 
included in the results of operations for the year ended june  was a non cash charge to operations of  in connection with the write down of goodwill and license and distribution rights acquired from eoi 
this write down was due to the impairment of value resulting from changes in the estimates of future sales associated with the license and distribution agreements 
no similar charges were incurred in fiscal during fiscal year  the company accrued  representing its anticipated contribution to settle the claims related to outstanding litigation george kozlowski v 
intelligent surgical lasers  inc  et al see note of the notes to consolidated financial statements for further details surrounding this litigation 
pursuant to the licensing agreement with intralase  the company is to be reimbursed  for previously expensed patent costs 
in october  the company recorded this receivable and credited marketing  general and administrative expense for this future reimbursement 
interest income decreased to  in fiscal year from  in fiscal year the decrease is due to a reduction in the levels of cash and cash equivalents available for investment prior to the completion of the preferred stock offering in january liquidity and capital resources at june  the company had cash and cash equivalents of  as compared to  at june  in addition  escalon now maintains a  certificate of deposit with pnc bank  na this investment is considered current and restricted  since it is pledged as collateral against the term loan 
the company s short term investments at june  and were and  respectively 
the net increase in cash and cash equivalents relates primarily to the betadine product line sale and borrowing against the line of credit 
the company anticipates that the cash and cash equivalents and the interest earned thereon  together with funds generated from future product sales  should be adequate to satisfy its capital requirements  based on current levels of operations  through the end of fiscal in the longer term  however  the company will seek corporate partnering  licensing and other fund raising opportunities necessary to satisfy the significant expenditures anticipated in connection with the development of its surgical products and ophthalmic drug delivery operations 
in january  the company entered into a financing agreement with pnc bank  na this agreement provided escalon a  line of credit outstanding at year end and subsequently repaid and a  five year term loan 
the line of credit expires on december  and has its interest rate set at prime plus one quarter of one percentage point at june  
the term loan has scheduled monthly repayments of  for principal plus interest through february the interest rate on this debt is percentage points above the rate payable on the restricted certificate of deposit that collateralizes the note at june  
all of the company s assets and cash collateral of  collateralize these agreements 
pursuant to various collaborative research and development  technology license and consulting arrangements relating to the company s drug delivery technology  the company has financial commitments of  to be paid during fiscal year   in fiscal year  and  in fiscal years  and as part of the asset purchase from radiance  the company is obligated to pay  once the vascular access technology transfer to wisconsin is complete 
the anticipated completion date will occur by the end of the first quarter of fiscal the company is also obligated to make minimum royalty payments in the amount of  to radiance for five years 
the board of directors authorized the repurchase of up to  shares of the company s common stock 
the price  timing and manner of these purchases will be at the discretion of management 
no purchases have been made  nor are any expected to be made  under this authority 
subsequent to year end  escalon sold its licensing and distribution rights to adatosil r silicone oil for million  payable in quarterly installments 
the first payment was received august  the company will receive additional cash consideration based on future silicon oil sales over the next six years 
the company anticipates additional expenditures may be incurred in connection with the legal proceedings as discussed in item legal proceedings 
as of june   the company had federal income tax and state income tax net operating loss carryforwards of approximately million and million  respectively 
under the provision of section of the internal revenue code  use of the company s net operating loss carryforwards is subject to an annual limitation as a change in ownership of more than occurred within a three year specified testing period 
federal and state net operating loss carryforwards will begin to expire in the company also had federal and state research credit carryforwards of  and  respectively  as of june  year issues none of the company s products use date sensitive software  therefore no customer service or support concerns need to be addressed 
the company does not utilize any custom developed programs  but rather commercially available off the shelf software packages with support contracts that specifically address this issue 
a year software upgrade for all financial packages is currently in place 
based on communications with our key suppliers  including utility and telecommunication providers  the year issue is being adequately addressed 
management judges the likelihood of temporary disruption of our manufacturing  customer service  sales and marketing  research and development or administrative functions to be minimal in regard to year compliance of our key suppliers and customers 
to date  the cost of year compliance has been insignificant 
any further activities are not expected to result in significant incremental operating expenses 
item a 
quantitative and qualitative disclosure about market risk none 

